{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:13:59Z","timestamp":1785208439765,"version":"3.55.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A qualitative abnormality of platelet function should be considered in patients with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand disease. Antiplatelet drugs are the most common cause of acquired platelet disorders leading to bleeding. Uremia, hepatic cirrhosis, myeloma and related disorders, polycythemia vera, essential thrombocythemia, and cardiopulmonary bypass have long been recognized as clinical situations in which platelet dysfunction may contribute to bleeding. When an acquired platelet disorder is suspected, it is useful to examine platelet function by measuring the bleeding time, examining platelet-dependent closure time in a platelet function analyzer and performing platelet aggregometry. When a specific acquired platelet disorder is diagnosed, many treatment options are available including controlling the underlying disease, giving platelet transfusions and administering a hemostatic drug.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.403","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"403-408","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Acquired Disorders of Platelet Function"],"prefix":"10.1182","volume":"2005","author":[{"given":"Amy A.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704130715300_R1","unstructured":"Coller BS, Schneiderman PI. Clinical evaluation of hemorrhagic disorders: the bleeding history and differential diagnosis of purpura. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology. Basic Principles and Practice, 4th Ed. Philadelphia, PA: Elsevier; 2005:1975\u20132000."},{"key":"2019111704130715300_R2","doi-asserted-by":"crossref","unstructured":"Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost. 2005;3:775\u2013777.","DOI":"10.1111\/j.1538-7836.2005.01245.x"},{"key":"2019111704130715300_R3","doi-asserted-by":"crossref","unstructured":"Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease\u2014a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol. 2000;108:259\u2013264.","DOI":"10.1046\/j.1365-2141.2000.01830.x"},{"key":"2019111704130715300_R4","doi-asserted-by":"crossref","unstructured":"Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhage: comparative study in 148 patients. J Thromb Haemost. 2004;2:892\u2013898.","DOI":"10.1111\/j.1538-7836.2004.00693.x"},{"key":"2019111704130715300_R5","doi-asserted-by":"crossref","unstructured":"Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost. 2003;90:483\u2013490.","DOI":"10.1160\/TH03-01-0004"},{"key":"2019111704130715300_R6","doi-asserted-by":"crossref","unstructured":"Michelson AD. Platelet function testing in cardiovascular disease. Circulation. 2004;110:e489\u2013e493.","DOI":"10.1161\/01.CIR.0000147228.29325.F9"},{"key":"2019111704130715300_R7","doi-asserted-by":"crossref","unstructured":"George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med. 1991;324:27\u201339.","DOI":"10.1056\/NEJM199101033240106"},{"key":"2019111704130715300_R8","doi-asserted-by":"crossref","unstructured":"Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:234S\u2013264S.","DOI":"10.1378\/chest.126.3_suppl.234S"},{"key":"2019111704130715300_R9","doi-asserted-by":"crossref","unstructured":"Amrein PC, Ellman L, Harris WH. Aspirin-induced prolongation of the bleeding time and perioperative blood loss. JAMA. 1981;245:1825\u20131828.","DOI":"10.1001\/jama.1981.03310430017013"},{"key":"2019111704130715300_R10","doi-asserted-by":"crossref","unstructured":"Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710\u2013713.","DOI":"10.1016\/S0741-5214(03)01029-2"},{"key":"2019111704130715300_R11","doi-asserted-by":"crossref","unstructured":"Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of ibuprofen. Ann Intern Med. 2005;142:506\u2013509","DOI":"10.7326\/0003-4819-142-7-200504050-00009"},{"key":"2019111704130715300_R12","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071\u20131080.","DOI":"10.1056\/NEJMoa050405"},{"key":"2019111704130715300_R13","doi-asserted-by":"crossref","unstructured":"Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081\u20131091.","DOI":"10.1056\/NEJMoa050330"},{"key":"2019111704130715300_R14","doi-asserted-by":"crossref","unstructured":"Fitzgerald GA. Coxibs and cardiovascular disease. N Eng J Med. 2004;351:1709\u20131711.","DOI":"10.1056\/NEJMp048288"},{"key":"2019111704130715300_R15","doi-asserted-by":"crossref","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med. 2001;345:1809\u20131817.","DOI":"10.1056\/NEJMoa003199"},{"key":"2019111704130715300_R16","doi-asserted-by":"crossref","unstructured":"Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174\u2013183.","DOI":"10.1055\/s-2005-869523"},{"key":"2019111704130715300_R17","doi-asserted-by":"crossref","unstructured":"Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142:251\u2013259.","DOI":"10.7326\/0003-4819-142-4-200502150-00007"},{"key":"2019111704130715300_R18","doi-asserted-by":"crossref","unstructured":"Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and\/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004;43:963\u2013981.","DOI":"10.2165\/00003088-200443140-00002"},{"key":"2019111704130715300_R19","doi-asserted-by":"crossref","unstructured":"Shattil SJ, Bennett JS, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest. 1980;65:329\u2013337.","DOI":"10.1172\/JCI109676"},{"key":"2019111704130715300_R20","doi-asserted-by":"crossref","unstructured":"Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247\u2013251.","DOI":"10.1161\/01.ATV.15.2.247"},{"key":"2019111704130715300_R21","unstructured":"Berenson A, Bayot J. Vision loss is reported in a few users of Viagra. New York Times. May 28, 2005."},{"key":"2019111704130715300_R22","doi-asserted-by":"crossref","unstructured":"Laine-Cessac P, Shoaay I, Garre JB, Glaud V, Turcant A, Allain P. Study of haemostasis in depressive patients treated with fluoxetine. Pharmacoepidemiol Drug Saf. 1998;7:S54\u2013S57.","DOI":"10.1002\/(SICI)1099-1557(199808)7:1+<S54::AID-PDS345>3.3.CO;2-Q"},{"key":"2019111704130715300_R23","doi-asserted-by":"crossref","unstructured":"Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther. 2002;27:391\u2013401.","DOI":"10.1046\/j.1365-2710.2002.00444.x"},{"key":"2019111704130715300_R24","doi-asserted-by":"crossref","unstructured":"Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:434\u2013439.","DOI":"10.1056\/NEJMoa022831"},{"key":"2019111704130715300_R25","doi-asserted-by":"crossref","unstructured":"Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004;30:579\u2013589.","DOI":"10.1055\/s-2004-835678"},{"key":"2019111704130715300_R26","doi-asserted-by":"crossref","unstructured":"Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123\u20131130.","DOI":"10.1053\/j.gastro.2004.07.015"},{"key":"2019111704130715300_R27","doi-asserted-by":"crossref","unstructured":"Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Eng J Med. 2004;350:114\u2013124.","DOI":"10.1056\/NEJMoa035572"},{"key":"2019111704130715300_R28","doi-asserted-by":"crossref","unstructured":"Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004;30:1873\u20131881.","DOI":"10.1007\/s00134-004-2388-0"},{"key":"2019111704130715300_R29","doi-asserted-by":"crossref","unstructured":"Rinder HM, Snyder EL, Tracey JB, et al. Reversibility of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion. 2003;43:1230\u20131237.","DOI":"10.1046\/j.1537-2995.2003.00484.x"},{"key":"2019111704130715300_R30","doi-asserted-by":"crossref","unstructured":"Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or \u2013injured mouse platelets. Blood. 2003;102:4229\u20134235.","DOI":"10.1182\/blood-2003-04-1305"},{"key":"2019111704130715300_R31","doi-asserted-by":"crossref","unstructured":"Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112:87\u201397.","DOI":"10.1016\/S0092-8674(02)01253-9"},{"key":"2019111704130715300_R32","doi-asserted-by":"crossref","unstructured":"Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP. Glycosylation restores survival of chilled blood platelets. Science. 2003;301:1531\u20131534.","DOI":"10.1126\/science.1085322"},{"key":"2019111704130715300_R33","doi-asserted-by":"crossref","unstructured":"Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325\u20131331.","DOI":"10.1111\/j.1537-2995.2004.04052.x"},{"key":"2019111704130715300_R34","doi-asserted-by":"crossref","unstructured":"Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RM Jr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg. 2002;235:820\u2013827.","DOI":"10.1097\/00000658-200206000-00009"},{"key":"2019111704130715300_R35","doi-asserted-by":"crossref","unstructured":"Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg. 2005;79:1210\u20131216.","DOI":"10.1016\/j.athoracsur.2004.09.046"},{"key":"2019111704130715300_R36","doi-asserted-by":"crossref","unstructured":"Eagle KA, Guyton RA, Davidoff R, et al. ACC\/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 guidelines for coronary artery bypass graft surgery). J Am Coll Cardiol. 2004;44:e252\u2013e253.","DOI":"10.1016\/j.jacc.2004.08.002"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/403\/645103\/403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/403\/645103\/403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:13:21Z","timestamp":1573982001000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/403\/19279\/Acquired-Disorders-of-Platelet-Function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.403","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}